A
A
Home

Press Releases

2022

September 21, 2022
argenx Submits Biologics License Application to U.S. Food and Drug Administration for Subcutaneous Efgartigimod for Treatment of Generalized Myasthenia Gravis
September 21, 2022
argenx to Highlight Key Programs from Neuromuscular Franchise at Upcoming Medical Meetings
September 8, 2022
argenx Appoints Camilla Sylvest to Board of Directors
argenx to Present at Wells Fargo Healthcare Conference
August 11, 2022
argenx Announces European Commission Approval of VYVGART™ (efgartigimod alfa-fcab) for the Treatment of Generalized Myasthenia Gravis
argenx Reports Half Year 2022 Financial Results and Provides Second Quarter Business Update
July 21, 2022
argenx to Report Half Year 2022 Financial Results and Second Quarter Business Update on July 28, 2022
June 24, 2022
argenx Receives Positive CHMP Opinion for Efgartigimod for the Treatment of Adult Patients with Generalized Myasthenia Gravis in Europe
argenx to Present at Upcoming Investor Conferences
May 31, 2022
argenx Announces the UK MHRA has Granted Early Access to Efgartigimod for Generalized Myasthenia Gravis
May 19, 2022
argenx Announces Publication of Translational Data of Efgartigimod in Autoimmune Skin Blistering Diseases
May 10, 2022
argenx announces results of Annual General Meeting of Shareholders